MDXH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDxHealth SA is not a good buy for a beginner, long-term investor at this time. The company is facing significant challenges, including a disappointing Q1 performance, a strategic exit from a key business segment, and reduced revenue guidance. Additionally, the technical indicators show a bearish trend, and there are no strong positive catalysts or trading signals to support a buy decision.
The MACD is positive and expanding, suggesting some bullish momentum, but the RSI is neutral at 32.399. Moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.521 and resistance at 0.559. Overall, the technical indicators point to a bearish outlook.
NULL identified. Analysts remain confident in the core prostate cancer business, but this is overshadowed by current challenges.
Significant revenue miss in Q1, discontinuation of the Resolve UTI business, and a $10M Medicare recoupment notice. Analysts have downgraded price targets significantly, and the company is undergoing operational restructuring.
No financial data available for analysis. However, analysts have noted a disappointing Q1 performance, with sales 9% below consensus and a material guidedown for 2026 revenue.
Analysts have downgraded the stock and significantly reduced price targets. William Blair downgraded the stock to Market Perform, while other firms reduced price targets to as low as $1.50. Analysts cite uncertainty due to the discontinuation of the Resolve UTI business and operational challenges.
